Notes on Psychiatric Medications with Alaska Context (SSRI, Stimulant, MAOI, Benzodiazepine, Anticonvulsant, Typical Antipsychotic)

SSRIs (Selective Serotonin Reuptake Inhibitors)

• Class overview: SSRIs are a larger class of antidepressants with six common examples mentioned:
  • citrulline (likely a misstatement for citalopram), escitalopram, fluoxetine, citalopram, paroxetine, and fluvoxamine. Zoloft (sertraline) is referenced as commonly used in practice.
• Indications for use:
  • Depression
  • Anxiety
  • Obsessive-compulsive disorder (OCD)
  • Post-traumatic stress disorder (PTSD)
  • Panic disorder
• Mechanism of action:
  • Block reuptake of serotonin in the brain, especially in the synaptic cleft, increasing serotonin availability to improve mood and alleviate depression/anxiety symptoms.
• Common adverse effects:
  • Blurred vision
  • Dizziness
  • Drowsiness
  • Dry mouth
  • Gastrointestinal upset (nausea)
  • Headache
  • Sexual dysfunction
• Contraindications (highest risk groups):
  • Pregnancy and breastfeeding
  • Contraindicated in children and adolescents
  • With blood thinners (especially aspirin and warfarin)
  • Serotonin-containing supplements (e.g., St. John’s Wort)
  • Allergies
  • Hepatic or renal disease (hepatorenal disease)
• Medication interactions (highlights):
  • With anticoagulants and antiplatelets (aspirin, warfarin) and NSAIDs
  • Alcohol and other CNS depressants
  • Monoamine oxidase inhibitors (MAOIs) and TCAs (risk of serotonin syndrome)
  • Opioids
  • OTC cold medications
  • Cocaine and migraine medications (triptans)
• Food interactions:
  • St. John’s Wort (reiterated as a serotonin-containing supplement failure risk)
  • Grapefruit, kava, valerian
• Nursing considerations:
  • Assess baseline signs/symptoms with physical assessment before initiation to establish baselines
  • Use with caution in renal/hepatic impairment; dose reductions in elderly
  • Monitor patient response regularly
• Teaching points for patients:
  • Do not quit abruptly; taper off gradually
  • Takes time to work; not immediate relief
  • Typical onset: around $4-6\text{ weeks}$ to see therapeutic effect
  • Take once daily in the morning (to align with daily routine and adverse effect profile)
  • Educate about potential drug and food interactions and what to avoid
• Dosing and titration (example workflow):
  • Start at $25\text{ mg}$ daily
  • Reassess after ~2 weeks; if inadequate, increase to $50\text{ mg}$ daily
  • If still not therapeutic after a couple weeks, consider further titration up to higher doses as per product labeling and patient response
• Desired outcome: reduction in depression and anxiety symptoms
• Clinical notes:
  • Serotonin syndrome risk if combined with other serotonergic agents; ensure thorough health history and gradual cross-taper when switching SSRIs
• Alaska-specific considerations (contextual relevance):
  • Seasonal affective depression (SAD) may be treated with SSRIs seasonally, starting in fall and tapering in spring
  • Telehealth can support ongoing monitoring and dose adjustments in remote settings
  • Baseline and periodic monitoring essential due to potential hepatic/renal considerations and regional access issues
• Practical clinical scenarios:
  • Example patient in Alaska with seasonal depression (addressing initiation, monitoring, and follow-up) via telehealth; emphasize starting at low dose and gradual titration with scheduled check-ins

Stimulants

• Common stimulants (examples mentioned):
  • Modafinil (Provigil)
  • Dextroamphetamine (and brand variants)
  • Methylphenidate (Ritalin) including brand names like Adderall (brand name for mixed amphetamine salts) elsewhere in discussion
  • Caffeine and nicotine noted as non-prescription stimulants
• Indications for use:
  • ADHD
  • Narcolepsy
  • Daytime sleepiness and fatigue associated with other medical conditions
• Mechanism of action:
  • Increase activity of the sympathetic nervous system by elevating synaptic dopamine and norepinephrine
  • Some may directly block sleep-promoting pathways or receptors
• Common adverse effects:
  • Hypertension
  • Appetite suppression
  • Insomnia
  • Nausea, vomiting, diarrhea
  • Headache, dizziness
  • Anxiety
  • Hyperkinesia, vertigo
  • Shortness of breath
• Contraindications:
  • Alcohol use (complicates cardiovascular/central effects)
  • Warfarin and SSRIs/SNRIs; MAOI interactions
  • Other antidepressants; antihypertensives; antihistamines; St. John’s Wort
  • Avoid concomitant use with certain stimulants or medications that increase sympathetic tone
• Medication interactions:
  • Alcohol, warfarin, MAOIs, SSRIs/SNRIs, fentanyl, antihistamines, certain oral contraceptives
  • Caffeine-containing foods/drinks may augment stimulation
  • St. John’s Wort can interact and increase effects of noradrenergic stimulation
• Food interactions: caffeine-containing foods/beverages can potentiate stimulation
• Nursing considerations and monitoring:
  • Monitor for cardiovascular effects (hypertension, tachycardia, arrhythmias)
  • Monitor for psychiatric symptoms (anxiety, irritability, mood changes)
  • CBC for long-term use; monitor vision changes
  • Black box warning for abuse, misuse, and addiction risk; ensure patient and caregiver education
  • Proper disposal of unused meds and safe storage; prevent misuse
• Administration and duration to onset:
  • Immediate-release formulations: typically $20-60\text{ minutes}$ to onset
  • Extended-release formulations: typically $45-120\text{ minutes}$ to onset
• Dosing considerations and team communication:
  • Recognize significant differences in dosing among similar agents (e.g., alprazolam vs diazepam discussion relates to benzodiazepines, not stimulants; highlights need for careful dose recognition across classes)
• Alaska-specific considerations:
  • Stimulants are controlled substances; stricter dispensing rules (e.g., 30-day supply, limited refills, some pharmacies require hard-copy prescriptions)
  • Difficulties for people in remote areas (fishing trips, away from pharmacies) to maintain consistent supply
  • Alternatives include Strattera (non-stimulant) for ADHD when stimulants are impractical or contraindicated
• Practice notes:
  • In busy clinical settings, educators emphasize ADHD diagnosis criteria before stimulant use
  • Use of stimulants requires careful assessment of eligibility and risk of misuse; not universally appropriate

Monoamine Oxidase Inhibitors (MAOIs)

• What MAOIs are: a class of antidepressants (examples listed: Nardil, Parnate, Marplan, MSAM)
• Rationale for use:
  • MAOIs inhibit monoamine oxidase enzymes, which metabolize serotonin and dopamine; by inhibiting these enzymes, they increase levels of monoamines
• Indications:
  • Symptoms indicating low serotonin or dopamine due to high monoamine oxidase activity
• Mechanism of action:
  • Inhibition of monoamine oxidase enzymes reduces breakdown of serotonin and dopamine, increasing their levels
• Common adverse effects:
  • Hypertension (tyramine-related hypertensive crises)
  • Serotonin syndrome risk
  • Nausea, vomiting, diarrhea
  • Headache, insomnia
• Contraindications:
  • Use with other antidepressants (risk of excessive monoamine activity)
  • Liver disease (metabolized in the liver)
  • Opioid use (increases risk of serotonin syndrome)
  • Pregnancy and breastfeeding
  • Potential interactions with other medications
• Interactions and dietary considerations:
  • Food interactions with tyramine-rich foods to avoid hypertensive crises
  • Tyramine-containing items include aged cheeses, smoked meats, fermented foods
• Nursing considerations:
  • Diet modification to restrict tyramine
  • Education on tyramine-rich foods and proper monitoring of blood pressure
  • Assess signs of serotonin syndrome; monitor blood pressure
• Teaching points:
  • Discuss diet and safe monitoring of blood pressure while on MAOIs
  • Self-regulation and monitoring for adverse effects
• Desired outcome:
  • Increased serotonin and dopamine levels to reduce depressive symptoms and fatigue
• Onset of action:
  • Typically effective within $2-3\text{ weeks}$, but may vary by drug
• Alaska-specific considerations:
  • Diet plays a prominent role due to traditional foods; cultural dietary habits must be considered to avoid noncompliance
  • Food choices in Alaska (e.g., smoked salmon, cheeses, fermented items) may impact adherence
• Patient and clinician reflections:
  • Noncompliance may reflect cultural dietary practices; emphasize culturally competent care and shared decision-making to select a medication compatible with lifestyle
• Example scenarios:
  • Using an MAOI in an Alaska Native patient with depressive symptoms requires careful dietary counseling and ongoing assessment of adherence and blood pressure

Benzodiazepines (BZDs)

• Common agents mentioned: alprazolam (Xanax), lorazepam (Ativan), diazepam (Valium), clonazepam (Klonopin), and others (e.g., temazepam is implied though not named here)
• Indications:
  • Anxiety disorders
  • Panic disorders
  • Seizures
  • Muscle spasms; sometimes used for sedation
• Mechanism of action:
  • Bind to GABA receptors in the brain, enhancing the inhibitory effect of GABA and producing a calming/sedative effect
• Routes and onset:
  • Multiple routes; onset varies by drug and route (oral, IV, IM; generally rapid for acute use)
• Common adverse effects:
  • Respiratory depression (especially with other CNS depressants)
  • Hypotension
  • Decreased GI motility
  • Dry mouth, dizziness, drowsiness, blurred vision
• Contraindications:
  • Hypersensitivity to the drug
  • Conditions with increased risk of respiratory depression (e.g., COPD, sleep apnea)
• Interactions and cautions:
  • CNS depressants (opioids, alcohol, general anesthesia, other muscle relaxants, antipsychotics)
  • Interactions with chamomile, kava kava, valerian (increasing sedation)
• Nursing considerations:
  • CNS depressant effects require monitoring for respiratory status and sedation
  • Potential for tolerance and dependence with long-term use
  • Assess liver function; monitor elderly and those with hepatic impairment due to metabolism
  • Instruct to take as prescribed, at the right dose and time, avoid abrupt discontinuation
  • Recommend taking at night due to sedation; monitor orthostatic changes when changing positions
  • Encourage non-pharmacologic strategies to manage anxiety; avoid alcohol and limit caffeine
• Desired outcomes:
  • Reduction in anxiety and agitation; sedation if used for agitation; possible reduction in seizure activity when used for seizures
• Dosing and safety notes:
  • Doses vary markedly between agents (e.g., Xanax uses smaller doses; diazepam used as a sedative with higher milligram dosing)
  • Use caution with driving or operating heavy machinery especially early in therapy
• Alaska-specific considerations:
  • High prevalence of alcohol use; assess for alcohol use disorder and coordinate with providers
  • Cultural considerations and patient honesty about alcohol use may affect prescribing decisions
• Clinical notes:
  • Consider potential for misuse or dependence; ensure coordinated care with prescribers

Anticonvulsants (Antiseizure Medications)

• Common agents listed: gabapentin, pregabalin, phenobarbital, phenytoin, clonazepam (note: clonazepam is a benzodiazepine; included here as used for seizures in some contexts), among others
• Indications:
  • Seizure disorders (epilepsy)
  • Off-label uses: anxiety, migraines, bipolar disorder, fibromyalgia, Parkinson’s disease, restless legs syndrome, neuropathic pain, alcohol withdrawal
• Mechanism of action:
  • Reduce neuronal excitability; modulate ion channels; influence GABAergic transmission in various ways depending on the drug
• Common adverse effects:
  • Headache, fatigue, dizziness, blurred vision
  • Nausea, weight changes, mood changes
• Contraindications:
  • Hypersensitivity to the drug
  • Caution in children and the elderly; breastfeeding considerations
• Interactions:
  • Interactions with older generation seizure medications and liver enzyme interactions
• Dietary and other interactions:
  • Grapefruit juice interference; high-fat diets can affect absorption for some agents
• Nursing considerations:
  • Take exactly as prescribed; do not skip doses
  • Monitor for suicidal ideation
  • Do not abruptly discontinue; monitor CNS depression and adjustments for diet interactions
  • Monitor liver function depending on the agent and patient
• Teaching points:
  • Adherence and dose maintenance are critical to prevent withdrawal seizures or relapse
  • Discuss diet and potential drug interactions with patients and caregivers
• Onset of efficacy:
  • Ranges from about $30\text{ minutes}$ to $4-6\text{ hours}$ to reach maximum therapeutic effect depending on the drug and route
• Alaska-specific considerations:
  • Often used for alcohol withdrawal management in Alaska
  • Potential impact on vitamin D metabolism due to lower sunlight exposure; monitor vitamin D levels as appropriate
• Patient considerations:
  • Use cautious selection given pregnancy status, liver function, and comorbidities; detailed patient history is essential

Typical Antipsychotics

• Potency categories and examples mentioned:
  • High potency: haloperidol (Haldol), perphenazine (Prolixin), pimozide (Orap), trifluoperazine (Stelazine)
  • Mid potency: fluphenazine (Trilafon), loxapine
  • Low potency: chlorpromazine (Thorazine), chlorpromazine derivatives (Mellaril)
• Indications:
  • Schizophrenia
  • Acute psychosis
  • Severe mania
  • Tourette’s syndrome
  • Severe agitation and aggression (as a sedative effect in some cases)
• Mechanism of action:
  • Block dopamine D2 receptors, reducing dopamine activity in mesolimbic pathways and other brain regions
• Common adverse effects (EPSEs and others):
  • Extrapyramidal symptoms: acute dystonia, Parkinsonism, tardive dyskinesia
  • Endocrine effects; weight gain; lethargy; sedation
  • Cardiac arrhythmias; hypotension
  • Sexual dysfunction
• Contraindications:
  • Hypersensitivity to the medication
  • CNS depression; conditions that prolong QT interval; Parkinson’s disease
• Interactions:
  • CNS depressants; anticholinergic medications; QT-prolonging drugs; antihypertensives; dopamine agonists; CYP4A/4F inhibitors or inducers; lithium
  • Food interactions: grapefruit; alcohol
• Nursing considerations:
  • Baseline medical history, physical exam, mental status assessment
  • Monitor for EPSEs and educate patients about warning signs
  • Monitor blood pressure and heart rate
  • Monitor for sedation; assess for dry mouth and urinary retention
• Teaching points:
  • Take as prescribed and avoid abrupt withdrawal to prevent relapse
  • Educate about EPSEs and how to counteract orthostatic hypotension
• Desired outcomes:
  • Reduction of positive symptoms (hallucinations, delusions, disorganized thinking)
  • Reduced agitation; improved thought organization; stabilized mood; improved overall functioning
• Onset and duration to effect:
  • Intramuscular (acute agitation or sedation): $30-60\text{ min}$ or 1-2 hours orally
  • Reduction of positive symptoms: typically $4-6\text{ weeks}$; stabilization of chronic psychosis may take months with continuous treatment
• Alaska-specific considerations:
  • Occasionally used for chemical restraint in dementia or severe agitation in Alaska clinical settings
  • Consideration of regional usage patterns and mobility to provide timely care

Alaska-Specific Considerations and Practical Context

• Seasonal depression and isolation:
  • SSRIs may be used seasonally for Seasonal Affective Disorder (SAD); dosing may start as days become shorter and sunlight decreases
  • Telehealth can support ongoing monitoring and dose adjustments for remote residents
• Monitoring and follow-up:
  • Periodic check-ins with healthcare providers to adjust dosing
  • Ensure continuity of medication supply; frozen or remote access challenges in Alaska
• Cultural competency and dietary considerations:
  • Diet and cultural practices (e.g., traditional foods high in tyramine for MAOIs) must be considered to avoid noncompliance
  • Importance of asking about lifestyle and dietary habits to tailor medication choices
• Telehealth and access to care:
  • Telehealth can facilitate routine screening (e.g., PHQ-9), dose adjustments, and adherence checks
  • Virtual follow-ups can help coordinate pharmacy deliveries and renewals for patients in remote communities
• Medication supply and logistics:
  • Some medications (especially stimulants) may have strict dispensing rules and limited refill options in Alaska; planning is essential for patients at sea or in remote locations
• Ethical and practical implications:
  • Respect patient autonomy and cultural practices when selecting medications
  • Avoid biased judgments about noncompliance; explore feasible alternatives that fit the patient’s lifestyle

Case Study: Mister Atka (Seasonal Depression in Alaska)

• Scenario: Mister Atka, living in Coctobic, experiences seasonal depression
• Proposed plan:
  • Consider SSRI initiation at a low dose (e.g., $25\text{ mg}$ daily) with telehealth-based monitoring
  • Schedule virtual check-ins every 1-2 weeks to assess symptom change (e.g., PHQ-9 or other screening tools)
  • If symptoms improve, maintain dose; if not, titrate to higher doses (e.g., $50\text{ mg}$, then $75-100\text{ mg}$ as needed) with medical oversight
  • Ensure a stable supply (often a 3-month supply is possible with insurance coverage)
  • Involve family or community support to reinforce medication adherence and monitoring
• Monitoring plan:
  • Baseline physical assessment with follow-up screenings to track improvement
  • Assess for adverse effects and suicidality
  • Reassess suitability of therapy at each telehealth visit
• Operational considerations:
  • If dose adjustments are needed, communicate clearly with the patient and confirm understanding via teleconference
  • Ensure patient access to the prescribed regimen, especially during winter months when travel is limited

Practical Nursing and Pharmacy Interplay (Key Takeaways)

• Nurses play a central role in:
  • Conducting baseline assessments and ongoing monitoring (PHQ-9, blood pressure, heart rate, signs of EPSEs, CNS depression, etc.)
  • Providing patient education on dosing schedules, tapering, and potential interactions
  • Coordinating with prescribers for dose adjustments based on check-in feedback
  • Screening for contraindications and documenting patient history, including dietary restrictions (especially for MAOIs)
• Important safety concepts:
  • Serotonin syndrome risk with serotonergic agents (SSRI + MAOI or SSRIs + other serotonergic drugs)
  • Abuse and dependence risk with stimulants and benzodiazepines; vigilant monitoring for misuse
  • Orthostatic hypotension risk with antipsychotics and benzodiazepines; advise gradual position changes
  • Long-term monitoring for metabolic effects, EPS (extrapyramidal symptoms), and mood changes with antipsychotics
• Documentation and care coordination:
  • Thorough health history to identify potential drug interactions and contraindications
  • Clear communication with patients about what symptoms warrant urgent care (e.g., suicidality, severe adverse effects)
  • Documentation of dosing changes, adherence status, and follow-up plans
• Real-world Alaska context:
  • Remote communities require flexible delivery and monitoring strategies (telehealth, mail-order pharmacies, multi-month supplies)
  • Cultural competence and respect for traditional foods and dietary patterns when counseling on diets (notably with MAOIs)
  • Emphasis on safe driving and daily functioning, especially when sedating medications are used

Summary of Key Timeframes and Doses (LaTeX-friendly references)

• SSRI onset often requires $4-6\text{ weeks}$ to achieve full effect
• Initial SSRI dose example: $25\text{ mg}$ daily; titration up to $50\text{ mg}$ or higher as needed
• Stimulant onset: various by formulation; e.g., immediate release $20-60\text{ minutes}$; extended release $45-120\text{ minutes}$ to onset
• MAOIs: effective typically within $2-3\text{ weeks}$; dietary restrictions to avoid tyramine-related hypertensive crises
• Benzodiazepine onset varies by agent and route; general sedative/anti-anxiety effects appear promptly, but abrupt cessation should be avoided
• Typical antipsychotics: onset for acute symptoms can be minutes to hours (IM/IV); stabilization of positive symptoms generally requires $4-6\text{ weeks}$; long-term control may take months

Quick Reference: Abbreviations and Terms

• SSRI: Selective Serotonin Reuptake Inhibitor
• MAOI: Monoamine Oxidase Inhibitor
• OCD: Obsessive-Compulsive Disorder
• SAD: Seasonal Affective Disorder
• PHQ-9: Patient Health Questionnaire-9 (depression screening tool)
• EPS: Extrapyramidal Symptoms
• CNS: Central Nervous System
• ADHD: Attention-Deficit/Hyperactivity Disorder
• STRATTERA: Atomoxetine (non-stimulant ADHD medication mentioned as alternative)